P

Piramal Pharma Ltd
NSE:PPLPHARMA

Watchlist Manager
Piramal Pharma Ltd
NSE:PPLPHARMA
Watchlist
Price: 249.1 INR 0.1%
Market Cap: 330.2B INR
Have any thoughts about
Piramal Pharma Ltd?
Write Note

Piramal Pharma Ltd
Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Piramal Pharma Ltd
Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash CAGR 3Y CAGR 5Y CAGR 10Y
P
Piramal Pharma Ltd
NSE:PPLPHARMA
Cash
â‚ą3.6B
CAGR 3-Years
299%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Cash
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Piramal Pharma Ltd
Glance View

Market Cap
328.8B INR
Industry
Pharmaceuticals

Piramal Pharma Ltd. engages in development and manufacturing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 0 full-time employees. The company went IPO on 2022-10-19. The firm has approximately 15 global facilities and a global distribution network in over 100 countries. The firm's subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC's complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.

PPLPHARMA Intrinsic Value
139.65 INR
Overvaluation 44%
Intrinsic Value
Price
P

See Also

What is Piramal Pharma Ltd's Cash?
Cash
3.6B INR

Based on the financial report for Mar 31, 2024, Piramal Pharma Ltd's Cash amounts to 3.6B INR.

What is Piramal Pharma Ltd's Cash growth rate?
Cash CAGR 3Y
299%

Over the last year, the Cash growth was 219%. The average annual Cash growth rates for Piramal Pharma Ltd have been 299% over the past three years .

Back to Top